The U.S. Food and Drug Administration (FDA) has approved 50 new molecular entities in 2024, with 24 designated as first-in-class therapies. This trend is expected to continue in 2025, with several first-in-class drugs set to be approved. These innovative treatments offer new approaches to challenging diseases, including schizophrenia, metabolic-associated steatohepatitis, and rare genetic disorders. Forecast…
A recent report by Clarivate highlights several blockbuster drugs poised to revolutionize the biotech industry. These treatments, expected to generate over $1 billion in sales, include CagriSema for type 2 diabetes, Awiqli for long-acting insulin, Cobenfy for schizophrenia, and several others. As these drugs make their way to market, they are expected to transform the…
The world of medicine is on the cusp of a revolution with the development of new weight-loss drugs and breakthroughs in various fields. Eli Lilly’s oral pill orforglipron and Amgen’s maritide are set to change the game in treating obesity and diabetes. Meanwhile, researchers are exploring the potential of GLP-1 agonists to treat other illnesses,…
A breakthrough in psychiatric medicine has been announced with the approval of KarXT, a schizophrenia drug that targets muscarinic receptors. This innovative approach has sparked excitement among researchers, but the road to success is long and challenging. Several similar drugs are in development, but the success of these medicines is not guaranteed. The recent failure…
A looming patent cliff threatens to disrupt the pharmaceutical industry, with over $200 billion in annual revenue at risk through 2030. However, this presents a significant opportunity for biosimilar developers to capitalize on the transition to more affordable treatments. Several companies, including Alvotech, Biocon Biologics, Celltrion, Formycon, and Samsung Bioepis, are already making strides in…
The biotech industry is witnessing a surge in the development of bispecific antibodies, a type of targeted therapy that can deliver two-in-one treatments to patients with cancer and other diseases. Several companies, including Adaptin Bio, Akeso, AP Biosciences, Candid Therapeutics, Summit Therapeutics, and Zenas BioPharma, are working on various bispecific antibody candidates, some of which…
A recent surge in interest in T cell engagers, a type of antibody engineered to redirect the immune system’s T cells to recognize and kill cancer cells, suggests that this field is set to take off. Several biotech companies have launched specifically to develop these medicines, and big names in the industry are investing in…
The biotech industry is witnessing a surge in the development of GPCR (G protein-coupled receptor) therapies, with eight promising biotechs acquiring funding to fortify their pipelines. These biotechs are working on various GPCR-targeted drugs to address numerous diseases, including neuropathic pain, cancer, and metabolic disorders. The market for GPCR drugs is expected to grow significantly,…
Multiple sclerosis is a chronic disease of the central nervous system that affects nearly one million people in the U.S. alone. Biotech companies are working to expand therapeutic options for the disease, which is currently treated with disease-modifying drugs. Several companies, including Biogen, Immunic Therapeutics, Kyverna Therapeutics, Progentos Therapeutics, TG Therapeutics, and Zenas BioPharma, are…
Researchers have made a significant discovery in understanding the molecular pathway behind endometriosis, a painful condition affecting millions of women worldwide. The study suggests that drugs already used to treat migraines could be effective in treating endometriosis by inhibiting a key protein that promotes pain and exacerbates the disease. This breakthrough offers new hope for…
